iPSC-Derived Oligodendrocytes

Introduction

Ipsc Derived Oligodendrocytes is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD
    IPSC["IPSC"] -->|"activates"| MOTOR_NEURONS["MOTOR NEURONS"]
    IPSC["IPSC"] -->|"activates"| STEM_CELLS["STEM CELLS"]
    IPSC["IPSC"] -->|"activates"| NEURON["NEURON"]
    IPSC["IPSC"] -->|"activates"| TAU["TAU"]
    IPSC["IPSC"] -->|"activates"| ORGANOIDS["ORGANOIDS"]
    IPSC["IPSC"] -->|"inhibits"| NEURON["NEURON"]
    IPSC["IPSC"] -->|"interacts with"| NEURON["NEURON"]
    Ipsc["Ipsc"] -->|"involved in"| Aging["Aging"]
    Ipsc["Ipsc"] -->|"associated with"| Midbrain_Dopaminergic_Neurons["Midbrain Dopaminergic Neurons"]
    IPSC["IPSC"] -->|"activates"| TDP_43["TDP-43"]
    IPSC["IPSC"] -->|"activates"| MICROGLIA["MICROGLIA"]
    IPSC["IPSC"] -->|"activates"| NEURODEGENERATION["NEURODEGENERATION"]
    Ipsc["Ipsc"] -->|"associated with"| Astrocytes["Astrocytes"]
    IPSC["IPSC"] -->|"causes"| NEURON["NEURON"]
    style IPSC fill:#4fc3f7,stroke:#333,color:#000

Induced pluripotent stem cell (iPSC)-derived oligodendrocytes are glial cells generated from patient-specific or healthy donor-derived iPSCs that can myelinate axons in the central nervous system. These cells offer unprecedented opportunities for disease modeling of demyelinating disorders, drug screening, and potentially cell replacement therapy for conditions like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS)^{1Efficient derivation of oligodendrocytes from ESCs (Nature Biotechnology, 2013)2013 · DOI 10.1038/nbt.2704Open reference2Scalable production of OPCs (Nature Methods, 2015)2015 · DOI 10.1038/nmeth.3447Open reference}.

Multi-Taxonomy Classification

Taxonomy Database Cross-References

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• Allen Brain Cell Atlas

• CellxGene Census

• Human Cell Atlas

• PanglaoDB

Differentiation Protocols

Overview

Generating oligodendrocytes from iPSCs involves a multi-stage process that recapitulates embryonic development:

1. Neural induction: Directing iPSCs toward neural fate

2. Patterning: Ventral neural tube patterning for oligodendrocyte lineage

3. Expansion: Proliferating oligodendrocyte progenitor cells (OPCs)

4. Maturation: Differentiating into myelinating oligodendrocytes

Key Signaling Molecules

• SHH (Sonic Hedgehog): Critical for ventral patterning

• FGF2 (Fibroblast Growth Factor 2): OPC proliferation

• PDGF-AA (Platelet-Derived Growth Factor): OPC survival and proliferation

• T3 (Triiodothyronine): Oligodendrocyte maturation

• CNTF (Ciliary Neurotrophic Factor): Maturation enhancement

• BMP inhibitors: Blocking astrocyte differentiation

Oligodendrocyte Progenitor Cells (OPCs)

Characterization

OPCs are the transit-amplifying stage between neural progenitors and mature oligodendrocytes:

• Proliferative: Can divide and expand in culture

• Migratory: Can migrate to demyelinated areas

• Plastic: Can dedifferentiate under certain conditions

Markers

• PDGFRA (PDGF Receptor Alpha): Early OPC marker

• NG2 (CSPG4): Chondroitin sulfate proteoglycan

• OLIG2: Transcription factor

• NKX2.2: Homeobox transcription factor

• SOX10: Sustains oligodendrocyte lineage

Mature Oligodendrocytes

Myelin Production

Mature oligodendrocytes produce myelin sheaths that wrap around axons:

• MBP (Myelin Basic Protein): Structural stability

• PLP1 (Proteolipid Protein 1): Major myelin protein

• MAG (Myelin-Associated Glycoprotein): Axonal recognition

• MOG (Myelin Oligodendrocyte Glycoprotein): Surface marker

Function

• Saltatory conduction: Enables rapid nerve impulse transmission

• Metabolic support: Provides lactate to axons

• Axonal maintenance: Prevents axonal degeneration

• Ion homeostasis: Regulates extracellular potassium

Disease Modeling Applications

Multiple Sclerosis

iPSC-derived oligodendrocytes model MS pathology:

• Demyelination mechanisms: Understanding immune-mediated myelin loss

• Remyelination failure: Why endogenous OPCs fail to repair

• Drug screening: Identifying compounds that enhance myelination

• Patient-specific models: Genetic variants affecting disease severity

Amyotrophic Lateral Sclerosis

Oligodendrocyte dysfunction in ALS:

• Reduced myelin production: Early feature of ALS pathology

• Metabolic support loss: Contributes to motor neuron degeneration

• SOD1 models: Reveals oligodendrocyte-specific vulnerabilities

• TDP-43 pathology: Oligodendrocyte involvement in protein aggregation

Periventricular Leukomalacia

Neonatal white matter injury:

• Preterm infant models: Understanding hypoxic-ischemic injury

• Developmental myelination: How injury affects myelin development

• Therapeutic interventions: Strategies to protect oligodendrocytes

Drug Screening Platforms

High-Throughput Screening

iPSC-derived oligodendrocytes enable drug discovery:

• Remyelination compounds: Screen for myelin regeneration

• Anti-inflammatory agents: Reduce immune attack on oligodendrocytes

• Neuroprotective drugs: Protect oligodendrocytes from death

• Differentiation enhancers: Promote OPC maturation

Key Compounds Identified

• Clemastine: Antihistamine promoting OPC differentiation

• Miconazole: Antifungal enhancing myelination

• Benztropine: Anti-parkinsonian with remyelination potential

• Opicinumab: Anti-LINGO-1 antibody in clinical trials

Cell Therapy Applications

Transplantation Strategies

Oligodendrocyte transplantation aims to repair demyelinated lesions:

• OPC transplantation: Less mature cells may integrate better

• Direct oligodendrocyte delivery: Mature cells for rapid myelination

• Biomaterial scaffolds: Enhance cell survival and integration

• Combination approaches: Cells plus neurotrophic factors

Challenges

• Survival: Low survival rates after transplantation

• Migration: Limited spread from injection site

• Maturation: Ensuring proper differentiation

• Immune response: Rejection of allogeneic cells

• Tumorigenicity: Risk of uncontrolled proliferation

Comparative Analysis

iPSC vs. ESC-Derived Oligodendrocytes

• Patient-specific disease modeling possible with iPSCs

• Autologous transplantation feasible

• Similar differentiation efficiency

• Both require purification for clinical use

vs. Adult OPCs

• iPSC-derived OPCs may have greater proliferative capacity

• Adult OPCs already committed to oligodendrocyte lineage

• iPSCs can be gene-corrected before differentiation

• Both face similar transplantation challenges

Future Directions

Research Priorities

• 3D brain organoids: Incorporating oligodendrocytes in assembloids

• Single-cell profiling: Understanding heterogeneity

• Gene editing: Correcting disease-causing mutations

• Automated platforms: Scalable manufacturing

Emerging Technologies

• iPSC banks: Clinical-grade cell lines for allogeneic therapy

• xenogeneic-free media: Clinical-grade differentiation protocols

• Non-integrating reprogramming: Safety improvements

• Disease-in-a-dish: Personalized medicine applications

Background

The study of Ipsc Derived Oligodendrocytes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• National Multiple Sclerosis Society - MS research and patient resources](/resources)

• ALS Association - ALS research and clinical trials](/clinical-trials)

• Myelin Repair Foundation - Myelin research

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC-Derived Oligodendrocytes discovered through SciDEX knowledge graph analysis:

graph TD
    FRONTOTEMPORAL_DEMENTIA["FRONTOTEMPORAL DEMENTIA"] -->|"activates"| IPSC["IPSC"]
    FIBROBLASTS["FIBROBLASTS"] -->|"activates"| IPSC["IPSC"]
    ASTROCYTES["ASTROCYTES"] -->|"activates"| IPSC["IPSC"]
    ALS["ALS"] -->|"activates"| IPSC["IPSC"]
    ALS["ALS"] -->|"regulates"| IPSC["IPSC"]
    CORTEX["CORTEX"] -->|"activates"| IPSC["IPSC"]
    AGING["AGING"] -->|"associated with"| IPSC["IPSC"]
    NEURONS["NEURONS"] -->|"activates"| IPSC["IPSC"]
    NF__B["NF-κB"] -->|"activates"| IPSC["IPSC"]
    MOTOR_NEURONS["MOTOR NEURONS"] -->|"activates"| IPSC["IPSC"]
    Stem_Cell["Stem Cell"] -->|"activates"| IPSC["IPSC"]
    AUTOPHAGY["AUTOPHAGY"] -->|"activates"| IPSC["IPSC"]
    Tdp_43["Tdp-43"] -->|"activates"| IPSC["IPSC"]
    AGING["AGING"] -->|"activates"| IPSC["IPSC"]
    STING["STING"] -->|"activates"| IPSC["IPSC"]
    style FRONTOTEMPORAL_DEMENTIA fill:#ef5350,stroke:#333,color:#000
    style IPSC fill:#4fc3f7,stroke:#333,color:#000
    style FIBROBLASTS fill:#80deea,stroke:#333,color:#000
    style ASTROCYTES fill:#80deea,stroke:#333,color:#000
    style ALS fill:#ef5350,stroke:#333,color:#000
    style CORTEX fill:#b39ddb,stroke:#333,color:#000
    style AGING fill:#4fc3f7,stroke:#333,color:#000
    style NEURONS fill:#4fc3f7,stroke:#333,color:#000
    style NF__B fill:#4fc3f7,stroke:#333,color:#000
    style MOTOR_NEURONS fill:#4fc3f7,stroke:#333,color:#000
    style Stem_Cell fill:#80deea,stroke:#333,color:#000
    style AUTOPHAGY fill:#4fc3f7,stroke:#333,color:#000
    style Tdp_43 fill:#81c784,stroke:#333,color:#000
    style STING fill:#ce93d8,stroke:#333,color:#000